For example, a study by Veggel et al. demonstrated the combination of afatinib with cetuximab showed moderate efficacy in patients with EGFR ex20ins-positive NSCLC, with a median PFS of 5.3 months (Bianca van Veggel, 2021) (Table 2). Here, EGFR is linked to non-small cell lung carcinoma.